Perineural Invasion and Risk of Lethal Prostate Cancer

Prostate cancer has a propensity to invade and grow along nerves, a phenomenon called perineural invasion (PNI). Recent studies suggest that the presence of PNI in prostate cancer has been associated with cancer aggressiveness. We investigated the association between PNI and lethal prostate cancer i...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer epidemiology, biomarkers & prevention Ročník 26; číslo 5; s. 719
Hlavní autoři:	Zareba, Piotr, Flavin, Richard, Isikbay, Masis, Rider, Jennifer R, Gerke, Travis A, Finn, Stephen, Pettersson, Andreas, Giunchi, Francesca, Unger, Robert H, Tinianow, Alex M, Andersson, Swen-Olof, Andrén, Ove, Fall, Katja, Fiorentino, Michelangelo, Mucci, Lorelei A
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.05.2017
Témata:	Adult Aged Cohort Studies Humans Male Middle Aged Neoplasm Grading - methods Neoplasm Invasiveness - pathology Peripheral Nerves - pathology Prostatic Neoplasms - pathology
ISSN:	1538-7755, 1538-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Prostate cancer has a propensity to invade and grow along nerves, a phenomenon called perineural invasion (PNI). Recent studies suggest that the presence of PNI in prostate cancer has been associated with cancer aggressiveness. We investigated the association between PNI and lethal prostate cancer in untreated and treated prostate cancer cohorts: the Swedish Watchful Waiting Cohort of 615 men who underwent watchful waiting, and the U.S. Health Professionals Follow-Up Study of 849 men treated with radical prostatectomy. One pathologist performed a standardized histopathologic review assessing PNI and Gleason grade. Patients were followed from diagnosis until metastasis or death. The prevalence of PNI was 7% and 44% in the untreated and treated cohorts, respectively. PNI was more common in high Gleason grade tumors in both cohorts. PNI was associated with enhanced tumor angiogenesis, but not tumor proliferation or apoptosis. In the Swedish study, PNI was associated with lethal prostate cancer [OR 7.4; 95% confidence interval (CI), 3.6-16.6; < 0.001]. A positive, although not statistically significant, association persisted after adjustment for age, Gleason grade, and tumor volume (OR 1.9; 95% CI, 0.8-5.1; = 0.17). In the U.S. study, PNI predicted lethal prostate cancer independent of clinical factors (HR 1.8; 95% CI, 1.0, 3.3; =0.04). These data support the hypothesis that perineural invasion creates a microenvironment that promotes cancer aggressiveness. Our findings suggest that PNI should be a standardized component of histopathologic review, and highlights a mechanism underlying prostate cancer metastasis. .
AbstractList	Background: Prostate cancer has a propensity to invade and grow along nerves, a phenomenon called perineural invasion (PNI). Recent studies suggest that the presence of PNI in prostate cancer has been associated with cancer aggressiveness.Methods: We investigated the association between PNI and lethal prostate cancer in untreated and treated prostate cancer cohorts: the Swedish Watchful Waiting Cohort of 615 men who underwent watchful waiting, and the U.S. Health Professionals Follow-Up Study of 849 men treated with radical prostatectomy. One pathologist performed a standardized histopathologic review assessing PNI and Gleason grade. Patients were followed from diagnosis until metastasis or death.Results: The prevalence of PNI was 7% and 44% in the untreated and treated cohorts, respectively. PNI was more common in high Gleason grade tumors in both cohorts. PNI was associated with enhanced tumor angiogenesis, but not tumor proliferation or apoptosis. In the Swedish study, PNI was associated with lethal prostate cancer [OR 7.4; 95% confidence interval (CI), 3.6-16.6; P < 0.001]. A positive, although not statistically significant, association persisted after adjustment for age, Gleason grade, and tumor volume (OR 1.9; 95% CI, 0.8-5.1; P = 0.17). In the U.S. study, PNI predicted lethal prostate cancer independent of clinical factors (HR 1.8; 95% CI, 1.0, 3.3; P =0.04).Conclusions: These data support the hypothesis that perineural invasion creates a microenvironment that promotes cancer aggressiveness.Impact: Our findings suggest that PNI should be a standardized component of histopathologic review, and highlights a mechanism underlying prostate cancer metastasis. Cancer Epidemiol Biomarkers Prev; 26(5); 719-26. ©2017 AACR.Background: Prostate cancer has a propensity to invade and grow along nerves, a phenomenon called perineural invasion (PNI). Recent studies suggest that the presence of PNI in prostate cancer has been associated with cancer aggressiveness.Methods: We investigated the association between PNI and lethal prostate cancer in untreated and treated prostate cancer cohorts: the Swedish Watchful Waiting Cohort of 615 men who underwent watchful waiting, and the U.S. Health Professionals Follow-Up Study of 849 men treated with radical prostatectomy. One pathologist performed a standardized histopathologic review assessing PNI and Gleason grade. Patients were followed from diagnosis until metastasis or death.Results: The prevalence of PNI was 7% and 44% in the untreated and treated cohorts, respectively. PNI was more common in high Gleason grade tumors in both cohorts. PNI was associated with enhanced tumor angiogenesis, but not tumor proliferation or apoptosis. In the Swedish study, PNI was associated with lethal prostate cancer [OR 7.4; 95% confidence interval (CI), 3.6-16.6; P < 0.001]. A positive, although not statistically significant, association persisted after adjustment for age, Gleason grade, and tumor volume (OR 1.9; 95% CI, 0.8-5.1; P = 0.17). In the U.S. study, PNI predicted lethal prostate cancer independent of clinical factors (HR 1.8; 95% CI, 1.0, 3.3; P =0.04).Conclusions: These data support the hypothesis that perineural invasion creates a microenvironment that promotes cancer aggressiveness.Impact: Our findings suggest that PNI should be a standardized component of histopathologic review, and highlights a mechanism underlying prostate cancer metastasis. Cancer Epidemiol Biomarkers Prev; 26(5); 719-26. ©2017 AACR. Prostate cancer has a propensity to invade and grow along nerves, a phenomenon called perineural invasion (PNI). Recent studies suggest that the presence of PNI in prostate cancer has been associated with cancer aggressiveness. We investigated the association between PNI and lethal prostate cancer in untreated and treated prostate cancer cohorts: the Swedish Watchful Waiting Cohort of 615 men who underwent watchful waiting, and the U.S. Health Professionals Follow-Up Study of 849 men treated with radical prostatectomy. One pathologist performed a standardized histopathologic review assessing PNI and Gleason grade. Patients were followed from diagnosis until metastasis or death. The prevalence of PNI was 7% and 44% in the untreated and treated cohorts, respectively. PNI was more common in high Gleason grade tumors in both cohorts. PNI was associated with enhanced tumor angiogenesis, but not tumor proliferation or apoptosis. In the Swedish study, PNI was associated with lethal prostate cancer [OR 7.4; 95% confidence interval (CI), 3.6-16.6; < 0.001]. A positive, although not statistically significant, association persisted after adjustment for age, Gleason grade, and tumor volume (OR 1.9; 95% CI, 0.8-5.1; = 0.17). In the U.S. study, PNI predicted lethal prostate cancer independent of clinical factors (HR 1.8; 95% CI, 1.0, 3.3; =0.04). These data support the hypothesis that perineural invasion creates a microenvironment that promotes cancer aggressiveness. Our findings suggest that PNI should be a standardized component of histopathologic review, and highlights a mechanism underlying prostate cancer metastasis. .
Author	Andersson, Swen-Olof Mucci, Lorelei A Giunchi, Francesca Rider, Jennifer R Finn, Stephen Tinianow, Alex M Flavin, Richard Fall, Katja Unger, Robert H Andrén, Ove Isikbay, Masis Pettersson, Andreas Gerke, Travis A Zareba, Piotr Fiorentino, Michelangelo
Author_xml	– sequence: 1 givenname: Piotr surname: Zareba fullname: Zareba, Piotr organization: Division of Urology, McMaster University, Hamilton, Ontario, Canada – sequence: 2 givenname: Richard surname: Flavin fullname: Flavin, Richard organization: Department of Pathology, Trinity College Dublin, Dublin, Ireland – sequence: 3 givenname: Masis surname: Isikbay fullname: Isikbay, Masis organization: Harvard Medical School, Boston, Massachusetts – sequence: 4 givenname: Jennifer R surname: Rider fullname: Rider, Jennifer R organization: Harvard T.H. Chan School of Public Health, Boston, Massachusetts – sequence: 5 givenname: Travis A surname: Gerke fullname: Gerke, Travis A organization: Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida – sequence: 6 givenname: Stephen surname: Finn fullname: Finn, Stephen organization: Department of Pathology, Trinity College Dublin, Dublin, Ireland – sequence: 7 givenname: Andreas surname: Pettersson fullname: Pettersson, Andreas organization: Clinical Epidemiology Unit, Department of Medicine, Solna, Stockholm, Sweden – sequence: 8 givenname: Francesca surname: Giunchi fullname: Giunchi, Francesca organization: Pathology Unit, Addarii Institute, S. Orsola-Malpighi Hospital, Bologna, Italy – sequence: 9 givenname: Robert H surname: Unger fullname: Unger, Robert H organization: Harvard T.H. Chan School of Public Health, Boston, Massachusetts – sequence: 10 givenname: Alex M surname: Tinianow fullname: Tinianow, Alex M organization: Harvard T.H. Chan School of Public Health, Boston, Massachusetts – sequence: 11 givenname: Swen-Olof surname: Andersson fullname: Andersson, Swen-Olof organization: School of Health and Medical Sciences, Örebro University, Örebro, Sweden – sequence: 12 givenname: Ove surname: Andrén fullname: Andrén, Ove organization: School of Health and Medical Sciences, Örebro University, Örebro, Sweden – sequence: 13 givenname: Katja surname: Fall fullname: Fall, Katja organization: School of Health and Medical Sciences, Örebro University, Örebro, Sweden – sequence: 14 givenname: Michelangelo surname: Fiorentino fullname: Fiorentino, Michelangelo organization: Pathology Unit, Addarii Institute, S. Orsola-Malpighi Hospital, Bologna, Italy – sequence: 15 givenname: Lorelei A surname: Mucci fullname: Mucci, Lorelei A email: lmucci@hsph.harvard.edu organization: Division of Public Health Sciences, University of Iceland, Reykjavik, Iceland
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28062398$$D View this record in MEDLINE/PubMed
BookMark	eNpNj1tLw0AQhRdR7EV_gpJHX7bupbOXRylVCwWL6HOYbicYTTd1NxH89wasIMMwhzkfB86EncY2EmNXUsykBHcrBQD33sBsuVlxabhQ2p6wsQTtuLUAp__0iE1yfhdCWA9wzkbKCaO0d2NmNpTqSH3CpljFL8x1GwuMu-K5zh9FWxVr6t4Gb5Pa3GFHxQJjoHTBzipsMl0e75S93i9fFo98_fSwWtyteTBSdxzNMDuNzgaLksKgqnmoNGEIvtJbrzWSEEYEMyzNlYbh4xUKrclSUFN285t7SO1nT7kr93UO1DQYqe1zKR0YcF7DfECvj2i_3dOuPKR6j-m7_OuqfgDkA1hR
CitedBy_id	crossref_primary_10_1080_2162402X_2017_1353860 crossref_primary_10_1007_s00345_020_03583_4 crossref_primary_10_1016_j_bbcan_2020_188406 crossref_primary_10_1002_adbi_202200046 crossref_primary_10_1016_j_biopha_2022_113691 crossref_primary_10_1016_j_acuroe_2022_02_004 crossref_primary_10_1111_his_14107 crossref_primary_10_1007_s10552_018_1049_5 crossref_primary_10_1016_j_canlet_2019_12_015 crossref_primary_10_1007_s00345_025_05749_4 crossref_primary_10_1038_s41585_019_0274_3 crossref_primary_10_1111_andr_12578 crossref_primary_10_3389_fonc_2020_01493 crossref_primary_10_1007_s00432_022_04540_x crossref_primary_10_3390_cancers16162794 crossref_primary_10_1097_JU_0000000000002963 crossref_primary_10_1016_j_currproblcancer_2025_101251 crossref_primary_10_1016_j_clgc_2024_102125 crossref_primary_10_1002_cam4_5701 crossref_primary_10_1016_j_biochi_2020_10_012 crossref_primary_10_4251_wjgo_v12_i5_592 crossref_primary_10_1097_MD_0000000000040087 crossref_primary_10_1016_j_heliyon_2025_e42293 crossref_primary_10_1002_pros_23936 crossref_primary_10_3390_biomedicines13081789 crossref_primary_10_4103_ijc_ijc_1550_21 crossref_primary_10_1016_j_mpdhp_2025_04_001 crossref_primary_10_1007_s00428_023_03574_x crossref_primary_10_1016_j_euf_2023_04_002 crossref_primary_10_1097_MS9_0000000000003204 crossref_primary_10_1186_s12943_024_02165_x crossref_primary_10_1016_j_ejso_2019_07_029 crossref_primary_10_3389_fonc_2022_1083150 crossref_primary_10_1038_s41388_020_01578_4 crossref_primary_10_3390_ijms26189257 crossref_primary_10_1038_s41467_020_18843_5 crossref_primary_10_3390_cancers14215246 crossref_primary_10_1016_j_acuro_2021_09_005 crossref_primary_10_3389_fonc_2020_00146 crossref_primary_10_1097_MD_0000000000019860 crossref_primary_10_1158_1078_0432_CCR_21_4543 crossref_primary_10_3390_ijms26146895 crossref_primary_10_1038_s41598_024_60538_0 crossref_primary_10_1016_j_canlet_2025_217497 crossref_primary_10_3390_cancers14174065 crossref_primary_10_1016_j_urolonc_2018_02_008 crossref_primary_10_3389_fonc_2021_710899 crossref_primary_10_1016_j_humpath_2020_07_005 crossref_primary_10_1002_mc_23127 crossref_primary_10_3389_fonc_2021_695251
ContentType	Journal Article
Copyright	2017 American Association for Cancer Research.
Copyright_xml	– notice: 2017 American Association for Cancer Research.
CorporateAuthor	Transdisciplinary Prostate Cancer Partnership (ToPCaP)
CorporateAuthor_xml	– name: Transdisciplinary Prostate Cancer Partnership (ToPCaP)
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1158/1055-9965.EPI-16-0237
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1538-7755
ExternalDocumentID	28062398
Genre	Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NCI NIH HHS grantid: UM1 CA167552 – fundername: NCI NIH HHS grantid: P01 CA055075 – fundername: NCI NIH HHS grantid: R01 CA141298 – fundername: NCI NIH HHS grantid: P50 CA090381
GroupedDBID	--- .55 18M 29B 2FS 2WC 34G 39C 3O- 53G 5GY 5VS 6J9 AAFWJ ABOCM ACPRK ADBBV ADCOW AENEX AFHIN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BR6 BTFSW C1A CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FRP H13 H~9 IH2 KQ8 L7B NPM OK1 P2P PQQKQ QTD RCR RHI SJN UDS VH1 W8F WHG WOQ X7M ZXP 7X8
ID	FETCH-LOGICAL-c613t-a6a6ad3a87c7a1ec3a8f4cf3eacc9f3b933ae0060c660ce423533a92a033e7ec2
IEDL.DBID	7X8
ISICitedReferencesCount	60
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000400524700008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1538-7755
IngestDate	Wed Oct 01 14:16:29 EDT 2025 Mon Jul 21 06:02:31 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Language	English
License	2017 American Association for Cancer Research.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c613t-a6a6ad3a87c7a1ec3a8f4cf3eacc9f3b933ae0060c660ce423533a92a033e7ec2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	http://kipublications.ki.se/Default.aspx?queryparsed=id:135753550
PMID	28062398
PQID	1856589354
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1856589354 pubmed_primary_28062398
PublicationCentury	2000
PublicationDate	2017-05-01
PublicationDateYYYYMMDD	2017-05-01
PublicationDate_xml	– month: 05 year: 2017 text: 2017-05-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Cancer epidemiology, biomarkers & prevention
PublicationTitleAlternate	Cancer Epidemiol Biomarkers Prev
PublicationYear	2017
References	12810209 - Urol Oncol. 2003 May-Jun;21(3):213-8 21411125 - Urology. 2011 Jul;78(1):121-5 24929427 - BMC Urol. 2014 Jun 14;14:49 10565752 - Urology. 1999 Nov;54(5):884-90 21437569 - Int J Clin Oncol. 2011 Oct;16(5):553-9 20675081 - Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1316-22 20869162 - Eur Urol. 2010 Dec;58(6):838-46 11521227 - Hum Pathol. 2001 Aug;32(8):828-33 21748758 - Prostate. 2012 Apr;72(5):542-8 16765530 - Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):403-7 15912782 - Hinyokika Kiyo. 2005 Apr;51(4):241-6 24292212 - J Natl Cancer Inst. 2013 Dec 18;105(24):1881-90 23495828 - Scand J Urol. 2013 Dec;47(6):443-8 17123267 - Cancer. 2007 Jan 1;109(1):13-24 25988518 - J Urol. 2015 Nov;194(5):1258-63 15187052 - JAMA. 2004 Jun 9;291(22):2713-9 10379750 - J Urol. 1999 Jul;162(1):103-6 26029290 - Can Urol Assoc J. 2015 May-Jun;9(5-6):E252-5 11746267 - Prostate. 2001 Nov 1;49(3):213-23 16046649 - JAMA. 2005 Jul 27;294(4):433-9 2769857 - J Urol. 1989 Sep;142(3):763-8 2427528 - J Cell Biol. 1986 Sep;103(3):929-45 17398023 - Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1053-8 18784981 - Int Urol Nephrol. 2009;41(3):581-6 24486077 - Mayo Clin Proc. 2014 Mar;89(3):308-18 11020557 - Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):629-33 6067543 - J Urol. 1967 Jun;97(6):1075-7 24463248 - J Natl Cancer Inst. 2014 Feb;106(2):djt430 19694710 - BJU Int. 2010 Jun;105(11):1510-3 19792046 - Arch Pathol Lab Med. 2009 Oct;133(10):1568-76 21165193 - Korean J Urol. 2010 Nov;51(11):745-51 12673714 - Cancer. 2003 Apr 15;97(8):1884-93 24768607 - Hum Pathol. 2014 Jul;45(7):1365-9 6155085 - Am J Surg Pathol. 1980 Apr;4(2):143-8 19047084 - Clin Cancer Res. 2008 Dec 1;14(23):7593-603 25339062 - Int J Urol. 2015 Feb;22(2):188-93 25998747 - Urol Oncol. 2015 Jul;33(7):330.e1-7 21953116 - Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2280-7 16096404 - Am J Surg Pathol. 2005 Sep;29(9):1159-63 14767286 - J Urol. 2004 Mar;171(3):1132-6 21820250 - Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e361-7 19602004 - Int J Urol. 2009 Aug;16(8):682-6 9052471 - Br J Urol. 1997 Feb;79(2):203-11 15538241 - J Urol. 2004 Dec;172(6 Pt 1):2249-51 24106869 - BJU Int. 2014 Jul;114(1):75-80 17656219 - Urology. 2007 Jul;70(1):111-6 23711540 - Eur Urol. 2014 Apr;65(4):802-8 25879548 - BMC Urol. 2015 Apr 08;15:27 11504751 - J Clin Oncol. 2001 Aug 15;19(16):3692-705 11125380 - J Urol. 2001 Jan;165(1):126-9 19389009 - BJU Int. 2009 Nov;104(9):1215-8 16707439 - Cancer Res. 2006 May 15;66(10):5159-64 21795075 - Urol Oncol. 2013 Feb;31(2):175-9 14697416 - Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24 16045776 - Histopathology. 2005 Aug;47(2):159-65 16286122 - Urology. 2005 Nov;66(5):1048-53 15342391 - Cancer Res. 2004 Sep 1;64(17):6082-90 19858401 - J Clin Oncol. 2009 Nov 20;27(33):5627-33 23374801 - Urology. 2013 Feb;81(2):354-7 19484787 - Cancer. 2009 Aug 1;115(15):3379-91 11912386 - J Urol. 2002 Apr;167(4):1675-80 9020270 - JAMA. 1997 Feb 12;277(6):467-71
References_xml	– reference: 21437569 - Int J Clin Oncol. 2011 Oct;16(5):553-9 – reference: 21411125 - Urology. 2011 Jul;78(1):121-5 – reference: 9052471 - Br J Urol. 1997 Feb;79(2):203-11 – reference: 11912386 - J Urol. 2002 Apr;167(4):1675-80 – reference: 15538241 - J Urol. 2004 Dec;172(6 Pt 1):2249-51 – reference: 19389009 - BJU Int. 2009 Nov;104(9):1215-8 – reference: 24106869 - BJU Int. 2014 Jul;114(1):75-80 – reference: 19047084 - Clin Cancer Res. 2008 Dec 1;14(23):7593-603 – reference: 21748758 - Prostate. 2012 Apr;72(5):542-8 – reference: 16765530 - Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):403-7 – reference: 25988518 - J Urol. 2015 Nov;194(5):1258-63 – reference: 16096404 - Am J Surg Pathol. 2005 Sep;29(9):1159-63 – reference: 19858401 - J Clin Oncol. 2009 Nov 20;27(33):5627-33 – reference: 24929427 - BMC Urol. 2014 Jun 14;14:49 – reference: 11746267 - Prostate. 2001 Nov 1;49(3):213-23 – reference: 21953116 - Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2280-7 – reference: 26029290 - Can Urol Assoc J. 2015 May-Jun;9(5-6):E252-5 – reference: 11504751 - J Clin Oncol. 2001 Aug 15;19(16):3692-705 – reference: 20675081 - Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1316-22 – reference: 24292212 - J Natl Cancer Inst. 2013 Dec 18;105(24):1881-90 – reference: 16707439 - Cancer Res. 2006 May 15;66(10):5159-64 – reference: 25998747 - Urol Oncol. 2015 Jul;33(7):330.e1-7 – reference: 24463248 - J Natl Cancer Inst. 2014 Feb;106(2):djt430 – reference: 19694710 - BJU Int. 2010 Jun;105(11):1510-3 – reference: 23495828 - Scand J Urol. 2013 Dec;47(6):443-8 – reference: 23711540 - Eur Urol. 2014 Apr;65(4):802-8 – reference: 6155085 - Am J Surg Pathol. 1980 Apr;4(2):143-8 – reference: 17123267 - Cancer. 2007 Jan 1;109(1):13-24 – reference: 6067543 - J Urol. 1967 Jun;97(6):1075-7 – reference: 24768607 - Hum Pathol. 2014 Jul;45(7):1365-9 – reference: 15912782 - Hinyokika Kiyo. 2005 Apr;51(4):241-6 – reference: 21165193 - Korean J Urol. 2010 Nov;51(11):745-51 – reference: 12810209 - Urol Oncol. 2003 May-Jun;21(3):213-8 – reference: 12673714 - Cancer. 2003 Apr 15;97(8):1884-93 – reference: 17656219 - Urology. 2007 Jul;70(1):111-6 – reference: 11020557 - Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):629-33 – reference: 17398023 - Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1053-8 – reference: 11521227 - Hum Pathol. 2001 Aug;32(8):828-33 – reference: 14697416 - Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24 – reference: 10565752 - Urology. 1999 Nov;54(5):884-90 – reference: 16046649 - JAMA. 2005 Jul 27;294(4):433-9 – reference: 16286122 - Urology. 2005 Nov;66(5):1048-53 – reference: 2427528 - J Cell Biol. 1986 Sep;103(3):929-45 – reference: 14767286 - J Urol. 2004 Mar;171(3):1132-6 – reference: 10379750 - J Urol. 1999 Jul;162(1):103-6 – reference: 19602004 - Int J Urol. 2009 Aug;16(8):682-6 – reference: 24486077 - Mayo Clin Proc. 2014 Mar;89(3):308-18 – reference: 15342391 - Cancer Res. 2004 Sep 1;64(17):6082-90 – reference: 25879548 - BMC Urol. 2015 Apr 08;15:27 – reference: 25339062 - Int J Urol. 2015 Feb;22(2):188-93 – reference: 18784981 - Int Urol Nephrol. 2009;41(3):581-6 – reference: 15187052 - JAMA. 2004 Jun 9;291(22):2713-9 – reference: 9020270 - JAMA. 1997 Feb 12;277(6):467-71 – reference: 19792046 - Arch Pathol Lab Med. 2009 Oct;133(10):1568-76 – reference: 2769857 - J Urol. 1989 Sep;142(3):763-8 – reference: 11125380 - J Urol. 2001 Jan;165(1):126-9 – reference: 23374801 - Urology. 2013 Feb;81(2):354-7 – reference: 19484787 - Cancer. 2009 Aug 1;115(15):3379-91 – reference: 21795075 - Urol Oncol. 2013 Feb;31(2):175-9 – reference: 16045776 - Histopathology. 2005 Aug;47(2):159-65 – reference: 21820250 - Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e361-7 – reference: 20869162 - Eur Urol. 2010 Dec;58(6):838-46
SSID	ssj0007955
Score	2.4877956
Snippet	Prostate cancer has a propensity to invade and grow along nerves, a phenomenon called perineural invasion (PNI). Recent studies suggest that the presence of... Background: Prostate cancer has a propensity to invade and grow along nerves, a phenomenon called perineural invasion (PNI). Recent studies suggest that the...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	719
SubjectTerms	Adult Aged Cohort Studies Humans Male Middle Aged Neoplasm Grading - methods Neoplasm Invasiveness - pathology Peripheral Nerves - pathology Prostatic Neoplasms - pathology
Title	Perineural Invasion and Risk of Lethal Prostate Cancer
URI	https://www.ncbi.nlm.nih.gov/pubmed/28062398 https://www.proquest.com/docview/1856589354
Volume	26
WOSCitedRecordID	wos000400524700008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7qRHzxfpk3IvgaZ5s2aZ5ExoYDN4oo7K2kaYJDaOc69_s9J-vYkyBIaSmUQjk5Od_XcyXkDihAnqtCM8QPFhkbMCUCwSJnjSicjERU-GETcjRKxmOVNg63ukmrXNlEb6iLyqCPvAO4AmCpeBw9Tr8YTo3C6GozQmOTtDhQGUzpkuN1t3Cp_NRTv6mljOOmgieIkw7OhWTA9eP7XjpgASbicvk7y_Ro09__73cekL2GZ9KnpWIckg1bHpGdYRNJPyYi9XV_2HSDDsqFRqcZ1WVBXyf1J60cfbHzD3iWYlUI8FHaRfWYnZD3fu-t-8yaGQrMAFDPmRZwFFwn0kgdWAN3LjKOg701yvFcca4tNmUxAk4L5Ar4n1ahfuDcSmvCU7JVVqU9J1TEPDdJ7kSikwgMgYaf2zyQptCBU4kL2-R2JZEMdBQDD7q01XedrWXSJmdLsWbTZTONDCO72IPw4g9vX5LdEFHV5xtekZaDHWqvybZZzCf17MYvPlxH6fAHReC3kw
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Perineural+Invasion+and+Risk+of+Lethal+Prostate+Cancer&rft.jtitle=Cancer+epidemiology%2C+biomarkers+%26+prevention&rft.au=Zareba%2C+Piotr&rft.au=Flavin%2C+Richard&rft.au=Isikbay%2C+Masis&rft.au=Rider%2C+Jennifer+R&rft.date=2017-05-01&rft.issn=1538-7755&rft.eissn=1538-7755&rft.volume=26&rft.issue=5&rft.spage=719&rft_id=info:doi/10.1158%2F1055-9965.EPI-16-0237&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7755&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7755&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7755&client=summon